Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2015

View Archived Issues

Dose-finding data from phase I study of AZD-8186 reported

Incyte presents the novel BET inhibitor INCB-054329

Generex announces buccal cannabis agreements

Pernix closes acquisition of Zohydro ER franchise

Novartis reviews key events of first quarter 2015

Scientists disclose new data on the effects of lorcaserin

Basmisanil has effects on EEG in subjects with Down syndrome

Re-analysis of phase II/III data support small-molecule drug CF-101 for psoriasis

Teva Pharmaceuticals relinquishes anticancer agent custirsen

First NDA submission for Merrimack Pharmaceuticals

AbbVie recalls milestones of first quarter 2015

SignalRx Pharmaceuticals discloses dual PI3K/BRD4 inhibitors

Columbia University presents SLC7A11 inhibitors

Infinity Pharmaceuticals discloses PI3K inhibitors

Cancer Research Technology patents HSF-1 inhibitors

CS Therapeutics introduces new ALK inhibitors

Mallinckrodt patents new berbines for cancer

Preclinical activity of BLU-554 prompts plans for a phase I trial

European orphan drug designation for VentiRx's motolimod in ovarian cancer

CPI-431-32 as a potential new treatment for HBV/HCV and HIV-1 coinfection

Dabrafenib and trametinib application filed in Japan for BRAF V600-mutated malignant melanoma

EMA classifies NeoStem's NBS-20 as advanced therapeutic medicinal product

Recruitment initiated in phase II trial of CicloMulsion for acute kidney injury

Daiichi Sankyo's edoxaban recommended for stroke prevention in Europe

Astellas launches Cresemba in the U.S. for invasive aspergillosis and invasive mucormycosis

DSMB recommends continuation of phase III trial of zoptarelin doxorubicin in endometrial cancer

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...